OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Backes Discusses PARP Inhibitor Combinations in Ovarian Cancer

March 23rd 2018

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Gomella on Screening in Prostate Cancer

March 22nd 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, encourages early screening for prostate cancer.

Dr. Gordan on Molecular Diagnostics in Biliary Tract Cancers

March 22nd 2018

John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.

Dr. Sonpavde on the Next Steps for Atezolizumab in Urothelial Carcinoma

March 22nd 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the next steps for the prognostic model for atezolizumab (Tecentriq) in patients with urothelial carcinoma.

Dr. Mesa Discusses the Treatment Landscape for MPNs

March 22nd 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment landscape for patients with myeloproliferative neoplasms (MPNs).

Dr. Hill Discusses Biomarker Research in MCL

March 22nd 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses biomarker research in mantle cell lymphoma (MCL).

Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALL

March 21st 2018

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.

Dr. Jahanzeb Discusses Advancements in Adjuvant HER2+ Breast Cancer

March 21st 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

Dr. Donnellan on Combinations Under Investigation in Acute Leukemia

March 21st 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.

Dr. Van Loon on the PROSPECT Trial

March 21st 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

Heather Greene on Immune-Related Adverse Events in Patients With NSCLC

March 21st 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses the most common immune-related adverse events (AEs) in patients with non–small cell lung cancer (NSCLC), and whether or not these AEs vary between agents.

Dr. Lonial Discusses Ongoing Phase III Trials in Multiple Myeloma

March 21st 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.

Dr. Wakelee Discusses EGFR TKIs in Lung Cancer

March 21st 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.

Dr. Domchek Discusses Immunotherapy in Breast Cancer

March 21st 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the development of immunotherapy in breast cancer.

Dr. Overman on the Impact of Nivolumab in mCRC

March 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Sacco on Ongoing Trials for Chemoradiation in Head and Neck Cancer

March 21st 2018

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.

Dr. West on Pain Management for Endometrial Cancer

March 21st 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses pain management for patients with endometrial cancer.

Dr. Kelley Discusses the Rising Incidence of HCC

March 20th 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.

Dr. Den Discusses Bone-Targeting Agents in Prostate Cancer

March 20th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

March 20th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).